BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 29, 2025
Breaking News: 100 days of uncertainty
See today's BioWorld Science
Home
» Chiesi Farmaceutici defines ALK5 inhibitors for idiopathic pulmonary fibrosis
To read the full story,
subscribe
or
sign in
.
Respiratory
Chiesi Farmaceutici defines ALK5 inhibitors for idiopathic pulmonary fibrosis
Aug. 8, 2023
Chiesi Farmaceutici SpA has patented TGF-β receptor type-1 (ALK5) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis.
BioWorld Science
Respiratory
Patents